Physician profile
Beata E Dizoglio
NPI 1558581165
$5,835.17
in general payments reported to CMS, 2019-2025
26 companies · $514 in 2025
The $514 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $151 · 2021: $377 · 2022: $675 · 2023: $2,534 · 2024: $1,064 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $1,511 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $1,511.16 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,994.56 | 2019-2025 | Liletta |
| Exeltis, USA INC. | $433.49 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $312.45 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $261.71 | 2022-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $260.59 | 2021-2022 | |
| Pfizer INC. | $208.42 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $192.27 | 2019-2025 | Gardasil 9, Gardasil |
| Allergan, INC. | $161.80 | 2019-2020 | |
| Coopersurgical, INC. | $117.26 | 2024-2025 | Paragard T 380a, Summit Doppler, Endosee |
| Mylan Pharmaceuticals INC. | $115.27 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.57 | 2022-2024 | |
| Exact Sciences Corporation | $89.70 | 2023-2025 | Cologuard Collection Kit |
| Sage Therapeutics, LLC | $89.50 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $84.29 | 2021-2022 | |
| Scynexis, INC. | $75.73 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $66.30 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $44.77 | 2021-2023 | |
| Evofem Biosciences, INC. | $38.51 | 2021-2022 | |
| Lupin INC. | $35.28 | 2019-2020 | |
| Medicem INC. | $26.83 | 2021 | |
| Covidien LP | $25.54 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $24.03 | 2025 | Exparel |
| Shield Therapeutics INC | $21.46 | 2024 | |
| Dexcom, INC. | $21.05 | 2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $19.40 | 2025 | Qelbree |
| Roche Diagnostics Corporation | $18.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beata Dizoglio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.